ClinicalTrials.gg

Program

HRS-9057

A development code. Also written as “HRS-9057 injection set” and “[14C]HRS-9057”.

Its studies are mostly in Heart Failure, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Nov 21, 20253 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine32 open or runningphase 2since Nov 21, 2025Jun 28, 2024none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-9057, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 28, 2024First study: phase 1 study in Heart Failure With Volume OverloadFirst studyNCT06506994 · 25 enrolled · China
  2. Nov 21, 2025Phase 2 study in Fluid Retention Caused by Heart FailurePhase 2 reachedNCT07318103 · 153 planned · China
  3. Jun 23, 2026Phase 1 study in Fluid Retention Due to Heart FailureNCT07681479 · 6 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07681479Fluid Retention Due to Heart Failure · China1Active, not recruitingAug 11, 20266
NCT07318103Fluid Retention Caused by Heart Failure · China2RecruitingSep 2026153
NCT06506994Heart Failure With Volume Overload · China1CompletedOct 29, 202525

How it is read

Names in the registry

  • “HRS-9057”, 2 entries
  • “HRS-9057 injection set”, 1 entry
  • “[14C]HRS-9057”, 1 entry

Codes read as this program: HRS9057.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.